Catalyst

Slingshot members are tracking this event:

NDA of Remoxy (oxycodone) Extended-Release Capsules CII expected to be refiled 1Q 2016

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
DRRX Community voting in process

Additional Information

Additional Relevant Details The extended release oxycodone market is ~$2.4 billion in the U.S. alone, and we are eligible for a potential royalty on REMOXY between 6.0% to 11.5% of net sales depending on sales volumes.
http://phx.corporate...
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 29, 2016
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Oradur, Extended-release Capsules Cii, Oxycodone, Remoxy, Nda, Pain Therapeutics